Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822726 | 1.00 | LMNA (0.37) | LMNAALOX15BLMPMP22LDHA | |
| SCHEMBL7266899 | 0.83 | TP53 (0.45) | LMNAALOX15BLMPMP22LDHA | |
| SCHEMBL126750 | 0.78 | TP53 (0.41) | SLC7A5TP53FFAR3LCKFYN | |
| SCHEMBL125330 | 0.78 | TP53 (0.41) | SLC7A5TP53FFAR3LCKFYN | |
| SCHEMBL125331 | 0.78 | TP53 (0.41) | SLC7A5TP53FFAR3LCKFYN | |
| SCHEMBL14584344 | 0.77 | FFAR3 (0.35) | TP53FFAR3LCKFYNTDP1 | |
| SCHEMBL304296 | 0.76 | TP53 (0.39) | SLC7A5TP53FFAR3LCKFYN | |
| SCHEMBL304298 | 0.76 | TP53 (0.39) | SLC7A5TP53FFAR3LCKFYN | |
| SCHEMBL7094019 | 0.75 | GABRR1 (0.33) | LMNAALOX15BLMPMP22 | |
| SCHEMBL5611346 | 0.74 | TP53 (0.33) | TP53FFAR3LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329756-B2 | Process for the manufacture of Isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-02-12 | — | — | US | claimed |
| US-20060167063-A1 | Process for the manufacture of isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-07-27 | — | — | US | claimed |
| WO-2005005437-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2005-01-20 | — | — | WO | claimed |
| CN-113317995-B | Dental restoration material for oral science and preparation method thereof | 云南中辉口腔医院有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-102174012-B | Preparation method of nimodipine | SHANDONG XINHUA PHARMACEUTICAL | 2013-03-20 | — | — | CN | disclosed |
| CN-102174012-A | Preparation method of nimodipine | SHANDONG XINHUA PHARMACEUTICAL | 2011-09-07 | — | — | CN | disclosed |
| US-7329756-B2 | Process for the manufacture of Isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-02-12 | — | — | US | disclosed |
| US-7329756-B2 | Process for the manufacture of Isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-02-12 | — | — | US | disclosed |
| US-20060167063-A1 | Process for the manufacture of isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| US-20060167063-A1 | Process for the manufacture of isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| WO-2005005437-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2005-01-20 | — | — | WO | disclosed |
| US-6689799-B1 | NON-NUCLEOSIDE-DERIVATIVE VIRICIDES | REPHARTOX (NL) | 2004-02-10 | — | — | US | disclosed |
| EP-1214315-B9 | 1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF | REPHARTOX (NL) | 2004-01-02 | — | — | EP | disclosed |
| EP-1214315-B1 | 1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF | REPHARTOX (NL) | 2003-05-02 | — | — | EP | disclosed |
| EP-1214315-A1 | 1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF | Rephartox (NL) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014370-A1 | 1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF | REPHARTOX (NL) | 2001-03-01 | — | — | WO | disclosed |
| EP-0461264-A1 | ETHYNYLPHENYL DERIVATIVE, PRODUCTION THEREOF, AND REMEDY FOR DISEASES OF CIRCULATORY ORGANS CONTAINING THE SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4675329-A | Isopropyl 2-(3-trifluoromethylphenoxy)-ethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate as vaso-dilators | BAYER AKTIENGESELLSCHAFT (DE) | 1987-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167063-A1 | Process for the manufacture of isradipine | ACMSD, AASDHPPT, DDC | LMNA 2467/4885ALOX15 1035/4885BLM 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.